home       
   
 
 
Scientific Publications

Tribody Technology

Schoonooghe S. et al. (2010). "PH1-derived bivalent bibodies and trivalent tribodies bind differentially to shed and tumour cell-associated MUC1". Protein Engineering Design and Selection 23(9):721-728.

Willems A et al. (2005). "CD3xCD28 cross-interating bispecofic antibodies improve tumor cell dependet T-cell activation". Cancer Immunol Immunother 54: 1059-1071.

Mertens N et al. (2004). "New Strategies in Polypeptide and Antibody Synthesis". Cancer Biotherapy & Radiopharmaceuticals 19(1): 99-109.

Willems A et al. (2003). "Optimizing expression and purification from cell culture medium of trispecific recombinant antibody derivatives". Journal of Chromatography B 786: 161–176.

Schoonjans R et al. (2000). "Fab Chains As an Efficient Heterodimerization Scaffold for the Production of Recombinant Bispecific and Trispecific Antibody Derivatives". The Journal of Immunology 165: 7050–7057. 

Schoonjans R et al. (2000). "Efficient heterodimerization of recombinant bi- and trispecific antibodies". Bioseparation 9: 179–183.

 

CAB051

Gelardi T et al. (2010). "Two novel human anti-ErbB2 immunoagents are active on trastuzumab-resistant tumours". British Journal of Cancer: 513-519.

Riccio G et al. (2009). "Cardiotoxic effects, or lack thereof, of anti-ErbB2 immunoagents". FASEB Journal 23(9): 3171-3178.

De Lorenzo C & D’Alessio G (2009). “Human anti-ErbB2 immunoagents-immunoRNases and compact antibodies”. FEBS Journal 276(6): 1527-1535.

Troise F et al. (2008). “Differential binding of human immunoagents and Herceptin to the ErbB2 receptor”. FEBS Journal 275(20): 4967-4979.

De Lorenzo C et al. (2007). “Combinatorial experimental protocols for Erbicin-derived immunoagents and Herceptin”. British Journal of Cancer 97(10): 1354-1360.

De Lorenzo C et al. (2005). “Biological properties of a human compact anti-ErbB2 antibody”. Carcinogenesis 26(11): 1890-1895.

De Lorenzo C et al. (2004). “A human, compact, fully functional anti-ErbB2 antibody as a novel antitumour agent”. British Journal of Cancer 91(6): 1200-1204.

 

Cardiotrophin

Marquès JM et al. (2007). "Cardiotrophin-1 is an essential factor in the natural defense of the liver against apoptosis". Hepatology 45(3): 639-648.

Iñiguez M et al. (2006). "Cardiotrophin-1 defends the liver against ischemia-reperfusion injury and mediates the protective effect of ischemic preconditioning". Journal of Experimental Medicine 203(13): 2809-2815.

Ho DW et al. (2006) "Therapeutic potential of cardiotrophin 1 in fulminant hepatic failure: dual roles in antiapoptosis and cell repair". Archives of Surgery 141(11): 1077-1084.

Bustos M et al. (2003). "Protection against liver damage by cardiotrophin-1: a hepatocyte survival factor up-regulated in the regenerating liver in rats". Gastroenterology 125(1): 192-201.

Yang ZF et al. (2008). “Cardiotrophin-1 enhances regeneration of cirrhotic liver remnant after hepatectomy through promotion of angiogenesis and cell proliferation". Liver International 28(5): 622-631.
 
Biotecnol has several R&D collaboration contracts focusing on both products and technology development. The results of such collaborations are usually published, hence helping validating such research, but also helping on the dissimination of the respective results